Melanoma is a cutting edge, comprehensive reference work on the topic of melanoma. The overarching goal is to provide detailed scholarly information which broadly covers all aspects of the clinical presentation and management of the disease, as well as the biological and scientific understanding of its pathogenesis and treatment. Key topics highlighted include recent breakthroughs in molecular diagnostics, breakthroughs in targeted therapeutic approaches, overviews of signaling and transcriptional pathways, and important controversies such as screening, early diagnosis, sentinel node biopsy, and prevention strategies. In all, the volume provides a cutting edge and comprehensive presentation of the field of melanoma, written by a team of internationally renowned thought-leaders.
David E. Fisher, MD, PhD, is chief of the Department of Dermatology at Massachusetts General Hospital (MGH). He also serves as director of Mass General's Cutaneous Biology Research Center, director of the Melanoma Center and Chair of the MGH Executive Committee on Research. A professor of dermatology and of pediatrics at Harvard Medical School, Dr. Fisher came to Mass General from the Dana-Farber Cancer Institute, where he previously directed the melanoma program. Dr. Fisher's research has focused on understanding the molecular and genetic events which underlie formation of melanoma as well as skin pigmentation. As a clinician, he has worked to translate these understandings into advances in diagnosis, treatment and prevention of human diseases related to the skin and associated disorders.
A graduate of Swarthmore College with a degree in biology and chemistry, Dr. Fisher is also an accomplished concert cellist and graduated from the Curtis Institute of Music in Philadelphia. He received his doctorate under Nobel Laureate Gunter Blobel and Henry Kunkel at Rockefeller University and his medical degree at Cornell University Medical College. Dr. Fisher's specialty training in Medicine, Pediatrics and Oncology were carried out at Dana-Farber Cancer Institute, Boston Children's Hospital, and Brigham and Women's Hospital, Harvard Medical School. His research contributions include elucidation of the pathway through which UV radiation induces pigmentation, identification of MITF as master transcriptional regulator in melanocytes and melanoma oncogene, novel approaches to melanoma treatment and prevention, and discovery of the link between ultraviolet radiation and addictive behaviors.
Boris C. Bastian, MD, received his medical degree from the University of Munich, Germany. He completed his residency in dermatology at the University of Würzburg, Germany. He did a postdoctoral fellowship at the Cancer Genetics Program at the University of California, San Francisco and joined the UCSF faculty in 1999 with appointments in dermatology and pathology. He served as the chair of the pathology department at Memorial Sloan-Kettering Cancer Center and was President of the Society of Melanoma Research from 2010 to 2013. In 2011 he returned to UCSF, where he now leads a research laboratory focused on the genetic underpinnings of skin cancer with the goal of improving disease classification and diagnosis, therapy, and prevention.
